Gene therapy could replace risky transplants for kids with hurler syndrome
NCT ID NCT06149403
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new gene therapy called OTL-203 against the standard stem cell transplant for children with Hurler syndrome, a rare genetic disorder. The therapy uses the child's own blood stem cells, modified to produce the missing enzyme, aiming to improve survival and reduce complications. 41 participants are enrolled, and the study compares event-free survival between the two treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OTL-203 (gene therapy using a patient's own stem cells modified to produce the missing IDUA enzyme)
What this could lead to
If successful, OTL-203 could become a safer and more effective alternative to standard stem cell transplant for children with Hurler syndrome, potentially reducing complications and improving outcomes.
What could go wrong
This is an early Phase 3 trial with only 41 participants, so results may not apply to all patients. Gene therapy carries risks like immune reactions or the treatment not working as expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPS-IH (HURLER SYNDROME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Manchester University NHS Foundation Trust Blood and Marrow Transplant Programme, Royal Manchester Children's Hospital
Manchester, M13 9WL, United Kingdom
-
Ospedale San Raffaele
Milan, 20131, Italy
-
Princess Maxima Center
Utrecht, 3584 CS, Netherlands
-
UMC Utrecht
Utrecht, 3584 CX, Netherlands
-
University of Minnesota, Pediatrics
Minneapolis, Minnesota, 55455, United States